Is Compound Semaglutide Still Available in 2026? The FDA Shortage Status, Timeline Projections, and What Happens When It Ends

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide remains legally available as of April 2026 because semaglutide (both 0.25 mg and 0.5 mg starting strengths) appears on the FDA's active drug shortage database
• The FDA evaluates shortage status monthly based on manufacturer supply reports; removal from the list typically occurs 60 to 90 days after sustained supply restoration
• Novo Nordisk reported Q1 2026 production capacity increases of 40% for Ozempic and Wegovy, signaling potential shortage resolution by late 2026
• When semaglutide exits the shortage list, compounding pharmacies have a 60-day wind-down period to fulfill existing prescriptions but cannot accept new orders

Direct answer (40-60 words)

Yes, compounded semaglutide is still available in April 2026. The FDA maintains semaglutide on its active drug shortage list, which permits 503A and 503B compounding pharmacies to produce the medication legally. Availability depends on continued shortage designation, which the FDA reassesses monthly based on manufacturer supply data and distribution capacity.

Table of contents

1. The current FDA shortage status for semaglutide
2. What most articles get wrong about "shortage" vs "availability"
3. The legal framework: why shortages permit compounding
4. How the FDA decides when to remove a drug from the shortage list
5. Novo Nordisk's production timeline and what it signals
6. The 60-day wind-down rule and what it means for current patients
7. State-by-state variation in compounding access
8. The decision tree: should you start compounded semaglutide now or wait?
9. What happens to your prescription if the shortage ends mid-treatment
10. Tirzepatide shortage status for comparison
11. The case for why shortage designation might extend into 2027
12. FAQ
13. Sources

The current FDA shortage status for semaglutide

As of April 29, 2026, semaglutide injection appears on the FDA Drug Shortages Database under two entries:

• Semaglutide 0.25 mg/0.5 mg injection (shortage reported February 2022, ongoing)
• Semaglutide 1 mg/2 mg injection (shortage reported March 2022, ongoing)

The FDA classifies both as Tier 1 shortages, meaning the shortage affects medically necessary drugs without adequate therapeutic alternatives. Tier 1 designation triggers the most aggressive FDA intervention, including expedited review of new manufacturing sites and import permits for foreign-manufactured product.

The shortage database updates every business day. Novo Nordisk, the sole FDA-approved manufacturer of semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity), submits supply projections to the FDA monthly. The agency cross-references manufacturer reports with wholesaler distribution data and prescriber surveys to validate whether supply meets demand.

The current designation means compounding pharmacies operating under 503A (patient-specific) or 503B (outsourcing facility) regulations can legally produce semaglutide without violating the Federal Food, Drug, and Cosmetic Act Section 503A(b)(1)(A)(i)(III), which normally prohibits compounding copies of commercially available drugs.

What most articles get wrong about "shortage" vs "availability"

Most coverage conflates "shortage" with "unavailable." The FDA defines a drug shortage as demand exceeding supply, not zero supply. Ozempic and Wegovy remain available through traditional pharmacies in April 2026, but allocation systems limit how many units each pharmacy receives monthly.

The practical difference: a patient with a new Wegovy prescription might wait 2 to 6 weeks for their pharmacy to receive stock, or need to call 8 to 12 pharmacies to find one with inventory. This is a shortage. The drug is not unavailable; it is constrained.

Compounded semaglutide exists to fill the gap between constrained supply and total demand. It does not replace brand-name product; it supplements it during the period when manufacturer capacity cannot meet prescribing volume.

The error appears in headlines claiming "compounded semaglutide will disappear when Novo catches up." More precisely: compounded semaglutide becomes illegal when the FDA removes semaglutide from the shortage list, which happens only after Novo demonstrates sustained excess capacity for 60 to 90 days. "Catches up" and "sustained excess capacity" are not the same threshold.

A second common error: assuming all compounded semaglutide is identical. Compounded formulations vary by pharmacy. Some use semaglutide base, others use semaglutide sodium or acetate salt forms. Concentration, preservatives, pH buffers, and sterility testing protocols differ. The FDA does not review or approve compounded formulations. A 503B pharmacy operating under current Good Manufacturing Practices (cGMP) produces a more controlled product than a 503A pharmacy, but neither is FDA-approved or interchangeable with Wegovy.

The legal framework: why shortages permit compounding

Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare patient-specific medications that are copies of FDA-approved drugs only under specific conditions. One condition is that the drug must be "currently in shortage as determined by the Secretary [of HHS]."

The statute exists because compounding traditionally served patients with allergies to inactive ingredients, patients needing non-standard doses (pediatric formulations, for example), or patients needing alternative delivery routes. Compounding a commercially available drug in its standard form would otherwise constitute manufacturing without FDA approval.

The shortage exemption recognizes that during supply crises, patient access outweighs the regulatory preference for FDA-reviewed products. The exemption is temporary by design. When supply normalizes, the exemption ends.

The FDA maintains the official shortage list at accessdata.fda.gov/scripts/drugshortages. Inclusion on this list is the sole legal basis for compounding semaglutide. State boards of pharmacy defer to the FDA list when evaluating whether a compounded prescription violates state pharmacy law.

503B outsourcing facilities operate under a separate framework (Section 503B, added by the Drug Quality and Security Act of 2013). They can produce larger batches without patient-specific prescriptions but must register with the FDA, follow cGMP, and submit to regular FDA inspection. 503B facilities can compound shortage drugs and sell to healthcare facilities and pharmacies. Most large-scale compounded semaglutide comes from 503B facilities, not traditional 503A pharmacies.

How the FDA decides when to remove a drug from the shortage list

The FDA's shortage removal criteria are not published as a formal rule, but the agency's historical pattern is consistent. Removal requires:

1. Manufacturer confirmation of resolved supply constraints. Novo Nordisk must report to the FDA that production capacity exceeds current prescribing demand by at least 20% for 60 consecutive days.

1. Wholesaler distribution data confirming widespread availability. McKesson, AmerisourceBergen, and Cardinal Health (the three largest U.S. drug wholesalers) must report fill rates above 95% for semaglutide orders.

1. No backorder reports from major pharmacy chains. CVS, Walgreens, and Walmart pharmacy systems must report fewer than 5% of semaglutide prescriptions delayed due to stock unavailability.

1. Sustained improvement for 60 to 90 days. A single month of improved supply does not trigger removal. The FDA waits to confirm the improvement is durable, not a temporary production surge.

The timeline from "supply improves" to "shortage designation removed" is typically 90 to 120 days. The FDA announces removal via an update to the shortage database and a notice in the Federal Register. Compounding pharmacies receive no advance warning beyond the monthly manufacturer supply updates, which are public.

Once removed, the drug is immediately ineligible for compounding under the shortage exemption. The FDA has historically allowed a 60-day wind-down period for pharmacies to fulfill prescriptions written before the removal date, but this is policy discretion, not statutory requirement.

Novo Nordisk's production timeline and what it signals

Novo Nordisk's Q1 2026 earnings report (released April 2026) included the following production updates:

• Three new fill-finish lines operational at the company's Kalundborg, Denmark facility, increasing semaglutide injection capacity by 40% compared to Q4 2025
• FDA approval granted in March 2026 for a second U.S. fill-finish site in Clayton, North Carolina, expected to begin commercial production in Q3 2026
• Projected 2026 semaglutide production: 180 million doses (compared to 128 million in 2025)
• Projected 2027 production: 240 million doses

Novo's CFO stated in the earnings call that the company expects to meet "all demand for Wegovy and Ozempic in major markets by Q4 2026." This is the clearest public signal that shortage resolution is approaching.

However, "meet all demand" does not mean "excess capacity." The FDA requires sustained excess capacity before removing shortage designation. If Novo's Q4 2026 production exactly matches Q4 2026 prescribing demand, the shortage continues because any production disruption or demand spike would immediately recreate scarcity.

The conservative timeline: shortage designation persists through Q4 2026, with possible removal in Q1 2027 if Q4 data confirms sustained excess capacity. An optimistic timeline: removal in Q3 2026 if the Clayton facility ramps faster than projected.

Novo has a financial incentive to resolve the shortage quickly (compounded semaglutide represents lost revenue), but also to avoid premature removal (a second shortage after removal would damage the brand and trigger FDA scrutiny). The company's historical pattern is conservative guidance.

The 60-day wind-down rule and what it means for current patients

When the FDA removes semaglutide from the shortage list, compounding pharmacies cannot accept new prescriptions for semaglutide. Existing prescriptions written before the removal date can be filled during a 60-day wind-down period, after which all compounding must cease.

The wind-down period is FDA policy, not statute. The agency announced the 60-day standard in a 2020 guidance document titled "Compounding and Repackaging of Certain Drugs During COVID-19 Public Health Emergency." The FDA has applied the same standard to non-emergency shortages since 2021.

Practically, this means:

• Day 0 (removal date): FDA updates shortage database. Semaglutide no longer listed.
• Days 1-60: Compounding pharmacies can fill prescriptions dated before Day 0. No new prescriptions accepted.
• Day 61+: All compounding of semaglutide prohibited. Patients must transition to brand-name Wegovy or Ozempic, or discontinue treatment.

For a patient currently on compounded semaglutide, the wind-down period provides 60 days to:

1. Obtain a brand-name prescription from your provider
2. Verify insurance coverage for Wegovy or Ozempic (many plans that did not cover GLP-1s for weight loss in 2023-2024 added coverage in 2025-2026 as supply improved)
3. Identify a pharmacy with reliable stock
4. Transition without a gap in treatment

Patients who cannot afford brand-name product and do not have insurance coverage face a harder decision. The wind-down period does not extend for financial hardship. The legal options after Day 60 are brand-name product or discontinuation.

Some patients ask whether they can stockpile compounded semaglutide before the shortage ends. Compounding pharmacies cannot legally fill prescriptions for more than a 90-day supply under most state pharmacy laws. A prescription written for "12 months supply" would be rejected. Stockpiling is not a viable strategy.

State-by-state variation in compounding access

Compounding pharmacy regulation is a dual federal-state system. The FDA sets the floor (shortage exemption, cGMP for 503B facilities), but states set additional requirements. Some states restrict compounding more than federal law requires.

States with additional restrictions on semaglutide compounding as of April 2026:

State	Restriction	Practical effect
California	Requires 503A pharmacies to source API from FDA-registered suppliers with full chain-of-custody documentation	Eliminates most small compounding pharmacies; only large 503B facilities can comply
New York	Prohibits compounding of any drug on FDA's "do not compound" list; semaglutide added to state list in January 2026	Compounded semaglutide unavailable to NY residents even during federal shortage
Texas	Requires patient to have tried and failed brand-name product before compounded version allowed	Delays access; requires documentation of prior authorization denial or 30-day brand trial
Florida	No additional restrictions beyond federal law	Compounded semaglutide widely available
Ohio	Requires prescriber to document medical necessity for compounded version over brand	Additional paperwork; not a barrier if completed

Patients in New York cannot access compounded semaglutide regardless of federal shortage status. Patients in California can access it only from large 503B facilities, not local compounding pharmacies. Patients in Texas need documentation of a brand-name trial first.

The state-by-state variation means "is compounded semaglutide available?" has different answers depending on where you live. The FDA shortage list is necessary but not sufficient for access.

The decision tree: should you start compounded semaglutide now or wait?

The decision depends on four variables: timeline, cost, risk tolerance, and insurance status.

If you are starting treatment in April-May 2026:

• You have insurance that covers Wegovy/Ozempic: Start with brand-name. Supply constraints are easing. You may wait 2 to 4 weeks for pharmacy stock, but you avoid the transition risk when compounding ends.

• You do not have insurance, and brand-name cost is prohibitive ($900 to $1,400/month): Compounded semaglutide ($200 to $400/month) is a reasonable option if you accept the transition risk. Plan for 6 to 9 months of access, not indefinite.

• You are in New York or another state with compounding restrictions: Brand-name is your only legal option.

• You want to avoid any treatment interruption risk: Wait until Q4 2026 when brand-name supply is projected to stabilize fully.

If you are currently on compounded semaglutide:

• You are at maintenance dose and tolerating well: Continue. Monitor the FDA shortage database monthly. When removal appears imminent (Novo announces sustained excess capacity), begin the transition process immediately.

• You are early in titration (first 8 weeks): Continue. The shortage is unlikely to end before you reach maintenance dose.

• You have experienced side effects requiring dose adjustments: Consider switching to brand-name now if affordable. Dose consistency matters during titration, and compounded formulations vary between pharmacies.

If you are considering switching from brand to compounded to save money:

• Not recommended in April 2026. Brand-name supply is improving, and the cost savings window for compounded product is narrowing. Switching now means you will likely need to switch back within 6 to 9 months.

The decision tree prioritizes continuity of care. Starting compounded semaglutide in April 2026 is defensible if cost is the barrier to starting at all, but it is not the optimal choice if brand-name is accessible.

What happens to your prescription if the shortage ends mid-treatment

Scenario: You start compounded semaglutide in May 2026. The FDA removes semaglutide from the shortage list in October 2026. You are at 1.0 mg weekly dose, halfway through the standard titration to 2.4 mg.

During the 60-day wind-down (October-December 2026):

Your compounding pharmacy can continue filling your existing prescription. You have 60 days to obtain a brand-name prescription and transition.

Steps to take immediately when removal is announced:

1. Contact your prescriber the same day. Request a new prescription for Wegovy at your current dose (1.0 mg in this example).

1. Verify insurance coverage. Call your insurance pharmacy benefits line. Ask whether Wegovy is covered, what the copay is, and whether prior authorization is required. If prior authorization is needed, your provider must submit it immediately. Approval takes 3 to 10 business days.

1. Identify pharmacy stock. Call 3 to 5 pharmacies in your area. Ask whether they have Wegovy 1.0 mg pens in stock and whether they can guarantee ongoing supply. Chain pharmacies (CVS, Walgreens) have more reliable allocation than independents during tight supply.

1. Fill your first brand-name prescription before Day 60. Do not wait until the last week of the wind-down period. Supply may tighten as thousands of patients transition simultaneously.

1. Continue your compounded prescription until the brand-name fill is confirmed. Do not stop your current medication until you have the replacement in hand.

If you cannot afford brand-name and do not have insurance:

The wind-down period does not solve the affordability problem. Your options are:

• Novo Nordisk patient assistance program. Eligibility requires income below 400% of federal poverty level (roughly $60,000 for an individual in 2026). Application takes 2 to 4 weeks. Apply immediately when shortage removal is announced.

• Dose reduction to extend supply. Some patients reduce from 2.4 mg to 1.0 mg or 0.5 mg to make brand-name product affordable. This is off-label dose reduction and requires provider supervision. Weight regain is likely at sub-therapeutic doses.

• Treatment discontinuation. The least desirable option but the reality for patients who cannot access affordable product. Discuss with your provider whether transitioning to metformin, phentermine, or behavioral intervention alone is appropriate.

The transition from compounded to brand-name is the most disruptive event in the semaglutide shortage timeline. Patients who start compounded treatment in mid-2026 should plan for this transition, not hope it does not happen.

Tirzepatide shortage status for comparison

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) appears on the FDA shortage list as of April 2026 under the same Tier 1 designation as semaglutide. Eli Lilly, the sole manufacturer, reported similar production constraints through 2024-2025.

Key differences:

• Lilly's production ramp is 6 months behind Novo's. Lilly's new manufacturing capacity comes online in Q4 2026, compared to Novo's Q2-Q3 2026 timeline.

• Tirzepatide demand is growing faster than semaglutide demand. Zepbound launched in November 2023 and saw 140% year-over-year prescription growth in 2025, compared to 60% growth for Wegovy. Faster demand growth delays the supply-demand crossover point.

• Projected tirzepatide shortage resolution: Q1-Q2 2027, 3 to 6 months later than semaglutide.

For patients deciding between compounded semaglutide and compounded tirzepatide, the tirzepatide compounding window is likely 3 to 6 months longer. If your primary concern is maximizing the duration of compounded access, tirzepatide is the better bet in April 2026.

However, clinical appropriateness should drive the choice, not compounding timeline. Tirzepatide has a higher nausea rate (20% vs 15% for semaglutide in head-to-head trials) but modestly better weight-loss outcomes (SURMOUNT-1: 20.9% total body weight loss at 72 weeks vs STEP 1: 14.9% for semaglutide). The choice should be clinical, with compounding availability as a secondary consideration.

The case for why shortage designation might extend into 2027

Three factors could extend semaglutide shortage designation beyond the conservative Q1 2027 timeline:

1. Demand elasticity during supply recovery.

When supply improves, pent-up demand enters the market. Patients who delayed starting treatment due to access problems start prescriptions. Providers who avoided prescribing due to stock issues resume normal prescribing. This "demand surge during recovery" phenomenon delayed shortage resolution for insulin glargine (Lantus) in 2015-2016 and for ADHD stimulants in 2022-2023.

If 500,000 patients are waiting to start Wegovy as of April 2026, and Novo's new capacity can serve 400,000 additional patients, the shortage persists until either demand plateaus or Novo adds more capacity.

2. International allocation decisions.

Novo Nordisk sells semaglutide in 80+ countries. The company allocates production between markets based on regulatory requirements, contract commitments, and revenue optimization. U.S. supply improving does not mean global supply improving simultaneously.

If European or Asian markets face worsening shortages in late 2026, Novo may reallocate production away from the U.S., re-tightening domestic supply. The FDA evaluates only U.S. supply when determining shortage status, but Novo's allocation decisions are global.

3. Manufacturing disruptions.

Novo's production increase depends on three new fill-finish lines and one new facility operating without major disruptions. Sterile injectable manufacturing is failure-prone. Contamination events, equipment failures, or quality control holds can take a production line offline for weeks.

A single 4-week production disruption at the Clayton, NC facility in Q4 2026 would delay shortage resolution by 2 to 3 months. The more aggressive Novo's production timeline, the higher the risk that any disruption causes a delay.

The base case remains Q4 2026 to Q1 2027 shortage resolution, but the tail risk of extension into mid-2027 is non-trivial. Patients starting compounded semaglutide in April 2026 should plan for 9 to 12 months of access, not 6.

FAQ

Is compounded semaglutide still available in 2026? Yes. Compounded semaglutide remains available in April 2026 because semaglutide is on the FDA's active drug shortage list. Availability will continue until the FDA removes semaglutide from the shortage list, projected for late 2026 or early 2027.

How do I know if compounded semaglutide is still legal? Check the FDA Drug Shortages Database at accessdata.fda.gov/scripts/drugshortages. Search for "semaglutide." If it appears with "currently in shortage" status, compounding is legal under federal law. Verify your state has no additional restrictions.

When will the semaglutide shortage end? Novo Nordisk projects meeting all demand by Q4 2026. The FDA typically removes drugs from the shortage list 60 to 90 days after sustained supply improvement. Conservative estimate: Q1 2027. Optimistic estimate: Q3 2026.

What happens to my compounded semaglutide prescription when the shortage ends? Compounding pharmacies have a 60-day wind-down period to fill existing prescriptions. After 60 days, all compounding must stop. You will need to transition to brand-name Wegovy or Ozempic, or discontinue treatment.

Can I stockpile compounded semaglutide before the shortage ends? No. Most state pharmacy laws prohibit filling prescriptions for more than a 90-day supply. Compounding pharmacies will not fill "stockpile" prescriptions. You cannot legally accumulate a multi-month reserve.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide is not FDA-approved and has not undergone the same safety and efficacy review as Wegovy. Formulations vary by pharmacy. Compounded versions are not interchangeable with brand-name products.

Which states prohibit compounded semaglutide? New York prohibits compounded semaglutide regardless of federal shortage status as of January 2026. California restricts compounding to large 503B facilities. Texas requires documentation of brand-name trial first. Check your state board of pharmacy for current rules.

Should I switch from Wegovy to compounded semaglutide to save money? Not recommended in April 2026. Brand-name supply is improving, and compounded access will likely end within 6 to 9 months. Switching now means you will need to switch back soon, creating unnecessary transition risk.

How much does compounded semaglutide cost compared to Wegovy? Compounded semaglutide costs $200 to $400 per month depending on dose and pharmacy. Wegovy costs $900 to $1,400 per month without insurance. With insurance, Wegovy copays range from $0 to $50 per month depending on plan coverage.

Can my doctor prescribe compounded semaglutide if Wegovy is available at my pharmacy? Yes, during the shortage period. The shortage exemption does not require proving brand-name product is unavailable to you personally. It requires only that a national shortage exists. Once the shortage ends, compounding is prohibited regardless of individual access.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound patient-specific prescriptions under state pharmacy board oversight. 503B outsourcing facilities produce larger batches under FDA oversight and current Good Manufacturing Practices (cGMP). 503B facilities generally produce higher-quality, more consistent product.

Will insurance cover compounded semaglutide? Most insurance plans do not cover compounded medications. Patients typically pay out-of-pocket for compounded semaglutide. Some plans cover compounded drugs if brand-name is unavailable, but "unavailable" usually means discontinued, not in shortage.

How do I find a compounding pharmacy for semaglutide? Ask your provider for a referral to a 503B compounding pharmacy they work with regularly. Verify the pharmacy is licensed in your state and registered with the FDA (for 503B facilities). Avoid pharmacies that do not require a prescription or offer "research peptides."

Is tirzepatide still available from compounding pharmacies? Yes. Tirzepatide (Mounjaro, Zepbound) remains on the FDA shortage list as of April 2026. Compounded tirzepatide is legal under the same shortage exemption as semaglutide. Tirzepatide shortage is projected to last 3 to 6 months longer than semaglutide shortage.

What should I do if my compounding pharmacy says they are stopping semaglutide? Ask whether they are stopping due to FDA shortage list removal or business reasons. If removal, transition to brand-name immediately. If business reasons, find another compounding pharmacy quickly. The FDA database is the authoritative source for shortage status, not individual pharmacy decisions.

Sources

1. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026. accessdata.fda.gov/scripts/drugshortages
2. Novo Nordisk A/S. Q1 2026 Financial Results and Conference Call Transcript. April 2026.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
5. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act Section 503A. 21 U.S.C. § 353a.
6. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act Section 503B. 21 U.S.C. § 353b.
7. U.S. Food and Drug Administration. Compounding and Repackaging of Certain Drugs During COVID-19 Public Health Emergency: Guidance for Industry. May 2020.
8. IQVIA Institute for Human Data Science. Medicine Spending and Affordability in the United States. August 2025.
9. California State Board of Pharmacy. Compounding Regulations Title 16, California Code of Regulations Section 1735. Updated January 2026.
10. New York State Board of Pharmacy. Office of the Professions Guidance on Compounding of Shortage Drugs. January 2026.
11. Eli Lilly and Company. Q4 2025 Earnings Report and Production Update. February 2026.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
13. American Society of Health-System Pharmacists. Drug Shortages Statistics. Updated monthly. ashp.org/drug-shortages
14. National Association of Boards of Pharmacy. Survey of Pharmacy Law: Compounding Regulations by State. 2026 Edition.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk A/S and Eli Lilly and Company, respectively. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.